Introduction

Sufentanil (sufentanil citrate) has been marketed in China since 2003. It has greater analgesic potency and a superior safety profile as compared to other fentanil derivatives.

Sufentanil is indicated for:

• Anesthesia during procedures including endotracheal intubation for artificial respiration.
• As an analgesic component of combination anesthesia.
• For the induction and maintenance of general anesthesia in major operations.